CTD Regional Requirements: Module 1 Differences Across FDA, EMA, Health Canada, and Japan
The ICH Common Technical Document (CTD) harmonizes Modules 2-5 across all ICH regions, but Module 1 is entirely region-specific. Each regulatory authority defines its own Module 1 structure, including application forms, prescribing information format, labeling, environmental assessment, risk management, and patent information. Sponsors filing globally must prepare separate Module 1 content for each target region.
Key Takeaways
Key Takeaways
- ICH CTD Modules 2-5 are harmonized across all ICH regions, but Module 1 is entirely region-specific and must be prepared separately for each target authority
- Prescribing information formats differ fundamentally: FDA requires USPI (PLR format), EMA requires SmPC (QRD template), Health Canada requires a bilingual Product Monograph, and PMDA requires a Japanese Package Insert
- Each region operates its own eCTD submission gateway with region-specific DTDs and controlled vocabularies; Module 1 XML cannot be reused across regions
- EMA and PMDA require a Risk Management Plan for all new drug submissions, while FDA requires REMS only for products with specific safety concerns
- ICH CTD regional requirements represent one of the most practical challenges in global regulatory submissions. While the ICH M4 guideline standardized the overall CTD structure and Modules 2-5 are harmonized across all ICH regions, Module 1 was intentionally left region-specific to accommodate each authority's administrative, legal, and procedural requirements.
- For regulatory teams managing multi-region filings, Module 1 preparation is where the greatest region-specific effort concentrates. The same drug substance and drug product data (Modules 3-5) can be submitted globally with minimal adaptation, but Module 1 must be prepared from scratch for each target region.
- In this guide, you will learn:
- Why Module 1 is region-specific and what the ICH CTD does not harmonize
- Section-by-section Module 1 comparison across FDA, EMA, Health Canada, and Japan
- Prescribing information and labeling format differences
- Application form requirements by region
- Environmental assessment and risk management differences
- Electronic submission gateway specifications
- Practical strategies for efficient multi-region Module 1 preparation
- ---
The ICH CTD Framework: What Is and Is Not Harmonized
ICH M4: The Common Technical Document
The ICH M4 guideline family (M4, M4Q, M4S, M4E) establishes the CTD as the standard format for pharmaceutical regulatory submissions across ICH regions. The CTD consists of five modules:
| Module | Content | Harmonized? |
|---|---|---|
| Module 1 | Administrative information and prescribing information | No - Region-specific |
| Module 2 | CTD summaries (Quality Overall Summary, Non-clinical/Clinical Overviews and Summaries) | Yes |
| Module 3 | Quality (CMC) data | Yes |
| Module 4 | Non-clinical study reports | Yes |
| Module 5 | Clinical study reports | Yes |
Why Module 1 Is Not Harmonized
Module 1 was excluded from harmonization because it contains:
- Administrative forms: Each country has its own application forms tied to national legal frameworks
- Prescribing information: Labeling formats are governed by national legislation and reflect country-specific medical practice
- Legal declarations: Patent certifications, environmental assessments, and other requirements that vary by jurisdiction
- Regulatory procedures: Fee structures, regulatory pathway designations, and procedural documents unique to each authority
This design was intentional. The ICH recognized that while scientific data could be standardized globally, administrative and legal requirements must remain sovereign.
Module 1 Structure Comparison: Overview
The following table provides a high-level comparison of Module 1 section assignments across four major ICH regions. Detailed content is covered in subsequent sections.
| Module 1 Section | FDA (US) | EMA (EU) | Health Canada | PMDA (Japan) |
|---|---|---|---|---|
| 1.0 | Cover Letter | Cover Letter | Cover Letter | N/A |
| 1.1 | Table of Contents | Table of Contents | Table of Contents | Table of Contents |
| 1.2 | Application Forms | Application Form | Application Forms | Application Form |
| 1.3 | Prescribing Information (USPI) | SmPC, PIL, Labeling | Product Monograph | Package Insert (Tenpu Bunsho) |
| 1.4 | Labeling | Mock-ups | Labeling | Labeling |
| 1.5 | Information for Review | GMP/GDP Certificates | Right of Reference | Application-related documents |
| 1.6 | Environmental Assessment | Environmental Risk Assessment | N/A (separate process) | Risk Management Plan |
| 1.7 | Pediatric Information | Orphan Drug | N/A | GMP-related documents |
| 1.8 | Other Regional Info | Pharmacovigilance | N/A | Data Integrity certificates |
| 1.9-1.15 | Various FDA-specific | Various EU-specific | Various HC-specific | Various JP-specific |
Section-by-Section Comparison
1.0 Cover Letter
| Region | Requirement |
|---|---|
| FDA | Required. Must identify the submission type, regulatory activity, product name, applicant, and include the submission tracking number (IND/NDA/BLA number) |
| EMA | Required. Must identify the procedure type (Centralised, DCP, MRP), product name, active substance, and applicant. Includes declaration of authenticity. |
| Health Canada | Required. Must identify submission type, drug name, active ingredient, proposed indication, and reference to any prior correspondence |
| PMDA | Not a separate document. Application form serves as the primary administrative document. |
1.2 Application Forms
Each region requires its own application form. These forms cannot be substituted for one another.
| Region | Form | Key Fields |
|---|---|---|
| FDA | FDA Form 356h (for NDA/BLA/ANDA) or FDA Form 1571 (for IND) | Applicant, product, application type, proposed indication, manufacturing sites, establishment registration numbers |
| EMA | Application Form (Module 1 of CTD for EU submissions) | Applicant, product, legal basis (Article 8(3), 10(1), 10(3), 10(4), etc.), MAH, QP details, proposed SmPC |
| Health Canada | HC/SC 3011 (Drug Submission Application Form) | Sponsor, submission type, drug product details, manufacturing sites, DIN (if applicable), attestation |
| PMDA | Shonin Shinsei-sho (Marketing Approval Application Form) | Applicant (must be Japanese entity), product details, manufacturing sites, proposed indications. Must be in Japanese. |
1.3 Prescribing Information
This section contains the most substantively different content across regions. Each authority requires a different prescribing information document with different format, content, and structural requirements.
Prescribing Information Format Comparison
| Dimension | FDA (USPI) | EMA (SmPC) | Health Canada (PM) | PMDA (Package Insert) |
|---|---|---|---|---|
| Document name | US Prescribing Information (USPI) | Summary of Product Characteristics (SmPC) | Product Monograph (PM) | Tenpu Bunsho (Package Insert) |
| Format authority | 21 CFR 201.56-57 (PLR format) | QRD template | HC PM template | MHLW notification format |
| Language | English | Language of member state (English for centralised) | English and French (bilingual for marketing) | Japanese |
| Highlights section | Required (since PLR 2006) | Not used | Not used | Not used |
| Boxed Warning | Black Box Warning | Not used (uses "Special warnings" section) | Bold warnings in PM | Contraindications with explanation format |
| Patient information | Separate document (PPI, Medication Guide, or Instructions for Use) | Package Leaflet (PL/PIL) - separate from SmPC | Part III of PM (Patient Medication Information) - within PM | Interview Form (separate from Package Insert) |
| Scientific data | Not in labeling | Not in SmPC (in EPAR) | Part II of PM includes pharmacology and toxicology summaries | Not in Package Insert (in Interview Form and review report) |
| Adverse reactions format | Listed by frequency with specific rates | Listed by MedDRA SOC and frequency categories | Listed by frequency categories | Listed by frequency categories (common, uncommon, rare) |
Key Content Differences in Prescribing Information
Clinical trial summaries:
- FDA: Not in USPI
- EMA: Not in SmPC (published in EPAR)
- Health Canada: Included in PM Part II
- PMDA: Not in Package Insert (in Interview Form)
Pharmacology and toxicology:
- FDA: Abbreviated in Clinical Pharmacology section of USPI
- EMA: Abbreviated in SmPC section 5 (Pharmacological Properties)
- Health Canada: Detailed summaries in PM Part II
- PMDA: Not in Package Insert; detailed in Interview Form
Drug interactions:
- FDA: Organized by clinical significance and mechanism in section 7
- EMA: Described in SmPC section 4.5
- Health Canada: Categorized by mechanism in PM
- PMDA: Described in Package Insert with Japanese clinical context
Patient Information Documents
| Region | Document | Location |
|---|---|---|
| FDA | Patient Package Insert (PPI), Medication Guide, or Instructions for Use | Separate from USPI; type depends on product |
| EMA | Package Leaflet (PL/PIL) | Separate document, user-tested per QRD template |
| Health Canada | Patient Medication Information (PMI) | Part III of the Product Monograph (within same document) |
| PMDA | Patient information provided through Interview Form | Interview Form is a separate document from Package Insert |
1.4 Labeling (Container Labels)
| Region | Requirements |
|---|---|
| FDA | Container labels per 21 CFR 201; includes NDC number, lot number, expiry, storage conditions, product identification |
| EMA | Mock-ups of inner and outer packaging per EU QRD template; must include safety features (unique identifier, anti-tampering device) per Falsified Medicines Directive (2011/62/EU) |
| Health Canada | Inner and outer labels per C.01.004; bilingual (English/French); DIN required; must include lot number, expiry, proper name |
| PMDA | Labels must comply with PMD Act requirements; Japanese language; includes approval number, manufacturing lot, expiry |
1.5 Regulatory Authority-Specific Information
This section varies significantly by region:
| Region | Content |
|---|---|
| FDA | Information for review: debarment certification, financial disclosure (21 CFR 54), patent information (for NDA: paragraph certifications under 505(b)(2) or 505(j)), field copy certification |
| EMA | GMP/GDP certificates from manufacturing sites, QP declarations, orphan drug certificates, paediatric investigation plan compliance |
| Health Canada | Right of Reference letters, Drug Master File (DMF) reference letters, Letters of Authorization |
| PMDA | Application-related documents: certificates, reference documents, prior consultation records (Sodan Kiroku references) |
1.6 Environmental Assessment
Environmental assessment requirements differ substantially:
| Region | Requirement |
|---|---|
| FDA | Environmental Assessment (EA) required under 21 CFR 25, or claim for categorical exclusion. Most NDAs qualify for categorical exclusion. If EA required, must include predicted environmental concentration and ecotoxicity data. |
| EMA | Environmental Risk Assessment (ERA) required per CHMP Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00 Rev. 1). Phase I and Phase II (if triggered) assessments. |
| Health Canada | Environmental assessment handled separately through the New Substances Notification Regulations under CEPA. Not a Module 1 document in the NDS. |
| PMDA | No separate environmental assessment requirement in Module 1. Environmental considerations addressed through other Japanese regulations. |
1.7-1.9 Additional Region-Specific Sections
FDA-specific:
- 1.7: Pediatric information (Pediatric Study Plans, pediatric use supplements)
- 1.8: Other FDA-specific requirements
- 1.9-1.12: Additional sections (REMS, if applicable)
EMA-specific:
- 1.7: Orphan drug designation and documentation
- 1.8: Pharmacovigilance system (PSMF summary, EU QPPV details)
- 1.9: Product information annexes
- 1.10-1.12: Paediatric information, additional annexes
Health Canada-specific:
- Sections beyond 1.5 are less structured; additional documents include attestation letters, agent authorization (for foreign sponsors), and fee documentation
PMDA-specific:
- 1.6: Risk Management Plan (J-RMP)
- 1.7: GMP-related documents and manufacturing site information
- 1.8: Data integrity certificates (GCP/GLP compliance declarations)
- 1.9-1.12: Orphan drug documentation, re-examination period requests, other JP-specific content
Risk Management Documents
Risk management requirements illustrate a significant area of regional divergence:
| Region | Document | Format |
|---|---|---|
| FDA | Risk Evaluation and Mitigation Strategy (REMS) | FDA-specific format; required only for products with specific safety concerns. Not required for all products. |
| EMA | Risk Management Plan (EU-RMP) | GVP Module V format; required for all MAA submissions. Includes safety specification, pharmacovigilance plan, and risk minimisation measures. |
| Health Canada | Risk Management Plan | Format based on EU-RMP with Canadian adaptations; expected for most NDS submissions with significant safety concerns |
| PMDA | Risk Management Plan (J-RMP) | Japan-specific format aligned with ICH E2E; required for most J-NDA submissions |
Key difference: EMA and PMDA require an RMP for essentially all new drug submissions. FDA requires a REMS only for specific products where safety concerns warrant it. This means sponsors filing globally should prepare an RMP for EMA/PMDA/HC and may or may not need a REMS for FDA.
Patent and Exclusivity Information
Each region handles patent and exclusivity information differently in Module 1:
| Region | Requirements |
|---|---|
| FDA | Patent certifications (Paragraph I-IV for ANDAs/505(b)(2) applications); patent information for listing in Orange Book; exclusivity claims |
| EMA | Data exclusivity declarations (Article 14(11) of Regulation 726/2004 or Article 10 of Directive 2001/83/EC); no patent linkage in regulatory process |
| Health Canada | Patent information for listing on the Patent Register; Certificates of Supplementary Protection (CSP) claims; data protection declarations under C.08.004.1 |
| PMDA | Re-examination period request (functions as de facto data protection); patent information not linked to regulatory process |
The FDA and Health Canada have patent linkage systems (Orange Book and Patent Register, respectively) that connect drug registration with patent status. EMA and PMDA do not have patent linkage mechanisms in their regulatory processes.
Electronic Submission Gateways
Each region operates its own electronic submission gateway with different technical specifications:
| Region | Gateway | Technical Details |
|---|---|---|
| FDA | Electronic Submissions Gateway (ESG) | WebTrader or AS2 connection; FDA-specific DTD for Module 1 XML; supports eCTD v3.2.2; transitioning to v4.0 |
| EMA | eSubmission Gateway / CESP (Common European Submission Platform) | eSubmission Web Client or Gateway; EU Module 1 DTD; supports eCTD v3.2.2; CESP for decentralised/MRP |
| Health Canada | Common Electronic Submissions Gateway (CESG) | Web-based portal; HC Module 1 DTD; supports eCTD v3.2.2 |
| PMDA | Gateway Submission System | PMDA-specific electronic submission system; JP Module 1 DTD; supports eCTD; submissions require Japanese entity registration |
Technical Compatibility Considerations
- eCTD backbone XML: Each region has its own DTD (Document Type Definition) for Module 1 XML elements. Module 1 XML cannot be reused across regions.
- Controlled vocabularies: Each region defines its own controlled vocabulary for document types, operations (new, append, replace, delete), and submission types. These vocabularies are not interchangeable.
- Modules 2-5 XML: The eCTD backbone for Modules 2-5 uses the same ICH DTD across all regions. Module 2-5 content can be reused with minimal adaptation.
- PDF specifications: All regions follow ICH specifications for PDF documents (fonts embedded, bookmarks, hyperlinks), but specific validation criteria may vary.
Practical Strategies for Multi-Region Module 1 Preparation
Strategy 1: Parallel Preparation with Shared Source Content
For prescribing information documents (USPI, SmPC, PM, Package Insert), sponsors should maintain a single source dataset of clinical and safety information from which each region-specific document is derived. This ensures consistency of medical content across all labeling documents while allowing format adaptation.
Source content that can be shared:
- Adverse reaction frequencies and descriptions
- Drug interaction data
- Pharmacokinetic parameters
- Clinical trial results summaries
- Contraindications and warnings (medical content, not format)
Content that must be region-specific:
- Document format and section ordering
- Treatment guidelines and medical practice references
- Regional drug names and nomenclature
- Language (Japanese, bilingual English/French for Canada)
- Regulatory cross-references (CFR sections, EU directives, etc.)
Strategy 2: Stagger Module 1 Preparation by Filing Sequence
If filing sequentially across regions (common for companies prioritizing one market first), prepare Module 1 for the first-filed region completely, then adapt for subsequent regions.
Common filing sequences:
- FDA first, then EMA, then HC/PMDA
- EMA first (Centralised), then FDA, then HC/PMDA
- Simultaneous FDA + EMA (requires parallel Module 1 preparation)
Strategy 3: Maintain a Module 1 Comparison Matrix
Maintain a living document that maps the Module 1 requirements across all target regions for each product. This matrix should identify:
- Which documents are required in each region
- Which documents have shared source content
- Regional deadlines and filing order
- Translation requirements
- Form completion responsibilities
Common Multi-Region Filing Pitfalls
| Pitfall | Impact | Prevention |
|---|---|---|
| Copying Module 1 content between regions | Submission rejection or queries | Prepare Module 1 from scratch for each region using region-specific templates |
| Inconsistent medical content across labeling | Regulatory queries, potential refusal | Maintain single source dataset for medical content |
| Wrong eCTD DTD for Module 1 | Technical validation failure | Verify DTD version and controlled vocabulary for each gateway |
| Missing region-specific documents | Screening rejection | Use region-specific Module 1 checklist before submission |
| Translation errors | Review delays, labeling deficiencies | Use qualified regulatory translators with domain expertise |
Emerging Harmonization Efforts
While Module 1 remains region-specific, several initiatives are working to reduce divergence:
ICH M1: Module 1 Administrative and Prescribing Information
ICH has explored harmonization of certain Module 1 elements through the M1 Expert Working Group. Progress has been limited due to the inherently national nature of administrative requirements, but areas of focus include:
- Standardizing submission unit descriptions
- Harmonizing controlled vocabulary where possible
- Aligning environmental risk assessment frameworks
- Exploring common elements in risk management plan formats
eCTD v4.0 (ICH M8)
The transition from eCTD v3.2.2 to v4.0 (FHIR-based) includes provisions for better handling of regional Module 1 content through a more flexible metadata structure. While Module 1 content will remain region-specific, the eCTD v4.0 architecture is designed to make regional adaptations more modular and less error-prone.
IDMP (ICH M5)
The Identification of Medicinal Products (IDMP) standards (ISO 11615, 11616, 11238, 11239, 11240) aim to create globally unique identification for medicinal products, substances, dosage forms, routes of administration, and units of measurement. When fully implemented, IDMP standards could reduce the administrative divergence in Module 1 by standardizing product identification across regions.
Regional Module 1 Quick Reference
FDA Module 1 Checklist
- [ ] Cover letter with NDA/BLA/IND number
- [ ] FDA Form 356h (or 1571 for IND)
- [ ] USPI in PLR format with Highlights
- [ ] Patient labeling (PPI, Medication Guide, or Instructions for Use, as applicable)
- [ ] Container/carton labeling
- [ ] Financial disclosure (21 CFR 54)
- [ ] Patent information (for NDA: Orange Book listing)
- [ ] Debarment certification
- [ ] Environmental Assessment or categorical exclusion
- [ ] Pediatric Study Plan or pediatric information
- [ ] REMS (if applicable)
- [ ] Field copy certification
EMA Module 1 Checklist
- [ ] Cover letter with procedure type identification
- [ ] EU Application Form
- [ ] SmPC (QRD template)
- [ ] Package Leaflet / PIL (QRD template, user-tested)
- [ ] Labeling mock-ups (inner/outer packaging)
- [ ] GMP/GDP certificates for all sites
- [ ] QP declarations
- [ ] Risk Management Plan (EU-RMP format)
- [ ] Environmental Risk Assessment
- [ ] Pharmacovigilance system (PSMF summary, EU QPPV)
- [ ] Paediatric Investigation Plan compliance
- [ ] Orphan designation (if applicable)
- [ ] Data exclusivity declaration
Health Canada Module 1 Checklist
- [ ] Cover letter
- [ ] HC/SC 3011 form
- [ ] Fee payment documentation
- [ ] Product Monograph (Parts I, II, III) using HC template
- [ ] Inner/outer labels (bilingual English/French)
- [ ] Right of Reference letters (if applicable)
- [ ] DMF reference letters (if applicable)
- [ ] Attestation letters
- [ ] Canadian agent authorization (for foreign sponsors)
- [ ] Risk Management Plan
PMDA Module 1 Checklist
- [ ] Shonin Shinsei-sho (Application Form, in Japanese)
- [ ] Japanese Package Insert (Tenpu Bunsho)
- [ ] Interview Form
- [ ] Label text (Japanese)
- [ ] Risk Management Plan (J-RMP)
- [ ] GMP-related documents
- [ ] Data integrity certificates (GCP/GLP compliance)
- [ ] Consultation record references (Sodan Kiroku)
- [ ] Re-examination period request (if applicable)
- [ ] Orphan drug designation (if applicable)
References
In principle, yes. Modules 2-5 follow the ICH CTD structure and can be submitted with the same content to FDA, EMA, Health Canada, PMDA, and other ICH region authorities. However, minor adaptations may be needed: clinical summaries may need to address region-specific population considerations (e.g., bridging study data for PMDA per ICH E5), and quality sections may need to reference different pharmacopoeia standards.